Benitec BioPharma (BNTC) PT Raised to $22 at Citizens After BB-301 Phase 1b/2a Study
Tweet Send to a Friend
Citizens analyst Silvan Tuerkcan raised the price target on Benitec BioPharma (NASDAQ: BNTC) to $22.00 (from $20.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
